摘要
膜型基质金属蛋白酶(MT1-MMP,MMP-14)与肿瘤的侵袭和转移相关,可导致患者预后较差。MT1-MMP介导了癌细胞的入侵,通过基底膜和细胞外基质的降解以及细胞迁移的诱导。然而,在癌间质中MT1-MMP的表达可以带动体内癌细胞浸润,提示了MT1-MMP也可以通过paracrinemediated机制促进肿瘤侵袭。在癌细胞转移的重要一步是上皮-间质转化(EMT),在癌细胞中从静止的上皮表型进化到一个更能动的间质表型。我们在这里发现,EMT是引发MT1 MMP介导TGF-β的信号通路,包括持续诱导CUTL1,Wnt5a表达内源性MT1-MMP。恢复上皮表型MT1-MMP与Smad4,CUTL1癌细胞间质,或Wnt5a表达或TGF-β的活性受到抑制。在MT1 MMP表达Wnt5a抑制了LNCaP细胞的下降,以及迁移和软琼脂生长。而MT1-MMP的表达不影响总TGF-β水平,MT1-MMP的催化活性增加了TGF-β的主动性,使MT1-MMP的表达细胞激活了EMT周围的细胞。MT1-MMP表达细胞共培养了non-mt1-mmp-expressing细胞的TGF-依赖过程。这些结果强调了,肿瘤的侵袭性可能扩大通过MT1 MMP介导TGF-β信号,使自分泌和旁分泌介导EMT的通路
关键词: MT1-MMP;EMT;TGF-ββ;CUTL1;前列腺癌。
Current Cancer Drug Targets
Title:MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Volume: 16 Issue: 7
Author(s): Hoang-Lan Nguyen, Pournima Kadam, Alex Helkin, Kevin Cao, Song Wu, Ghassan J. Samara, Qian Zhang, Stanley Zucker, Jian Cao
Affiliation:
关键词: MT1-MMP;EMT;TGF-ββ;CUTL1;前列腺癌。
摘要: Membrane type 1-matrix metalloproteinase (MT1-MMP, MMP-14) is associated with cancer invasion and metastasis leading to poor patient prognosis. MT1-MMP mediates cancer cell invasion via degradation of basement membrane and extracellular matrix, and induction of cell migration. However, MT1-MMP expression in the cancer stroma can drive invasion of carcinoma cells in vivo, suggesting MT1-MMP may also promote cancer invasiveness via paracrinemediated mechanisms. A major step in cancer cell metastasis is thought to be an epithelial-mesenchymal transition (EMT), in which carcinoma cells evolve from a stationary epithelial phenotype to a more motile mesenchymal phenotype. We demonstrate here that EMT is triggered by MT1-MMP-mediated activation of TGF-β signaling, involving induction of CUTL1 and subsequently, of Wnt5a. Mesenchymal-like cancer cells expressing endogenous MT1-MMP reverted to an epithelial phenotype when MT1-MMP, SMAD4, CUTL1, or Wnt5a expression or TGF-β activity was inhibited. Wnt5a knockdown in MT1- MMP expressing LNCaP cells caused decreased cell migration and cell growth in soft agar. While MT1-MMP expression did not affect total TGF-β level, MT1-MMP catalytic activity increased the availability of active TGF-β, enabling MT1-MMP-expressing cells to activate the EMT in nearby cells. MT1-MMP-expressing cells induced co-cultured non-MT1-MMP-expressing cells to undergo EMT by a TGF-β-dependent process. These results highlight a pathway by which tumor invasiveness may be expanded via MT1-MMP-mediated activation of TGF-β signaling, enabling autocrine and paracrine-mediated induction of EMT.
Export Options
About this article
Cite this article as:
Hoang-Lan Nguyen, Pournima Kadam, Alex Helkin, Kevin Cao, Song Wu, Ghassan J. Samara, Qian Zhang, Stanley Zucker, Jian Cao , MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/1568009616666160216125634
DOI https://dx.doi.org/10.2174/1568009616666160216125634 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype
MicroRNA Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes
Current Radiopharmaceuticals Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Recent Advancements in Nanotechnology for Oral Cancer: a Review
Current Drug Therapy NBS1 Heterozygosity and Cancer Risk
Current Genomics Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Systematic Analysis of the Expression Profile and Prognostic Significance of the IGF2BP Family in Lung Adenocarcinoma
Current Cancer Drug Targets The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Current Pharmaceutical Design